Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 22, 2015

Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Effects of Low-Dose Naltrexone on Quality of Life and Fatigue in Newly Diagnosed High-Grade Glioma (P4.210)

Katherine Peters, Mary Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, Charlene Flahiff, Elizabeth Miller, Maria Freeman, Janet Minchew, Ben Zalutsky, Bonnie Taylor, Susan Boulton, Dina Randazzo, Annick DesJardins, Gordana Vlahovic, Darell Bigner, Henry Friedman
First published April 8, 2015,
Katherine Peters
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Affronti
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Woodring
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Lipp
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Healy
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances McSherry
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Herndon
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlene Flahiff
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Miller
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Freeman
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet Minchew
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Zalutsky
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonnie Taylor
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Boulton
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dina Randazzo
1Durham NC United States
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annick DesJardins
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordana Vlahovic
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darell Bigner
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Friedman
2Duke University Medical Center Durham NC United States
3Duke University Medical Center Durham NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Placebo-Controlled, Double-Blind, Randomized Pilot Study to Evaluate the Effects of Low-Dose Naltrexone on Quality of Life and Fatigue in Newly Diagnosed High-Grade Glioma (P4.210)
Katherine Peters, Mary Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, Charlene Flahiff, Elizabeth Miller, Maria Freeman, Janet Minchew, Ben Zalutsky, Bonnie Taylor, Susan Boulton, Dina Randazzo, Annick DesJardins, Gordana Vlahovic, Darell Bigner, Henry Friedman
Neurology Apr 2015, 84 (14 Supplement) P4.210;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Background: During the illness trajectory of high-grade glioma (HGG), patients experience diminished quality of life (QoL) and fatigue associated with diagnosis and treatment, in particular chemoradiation. Naltrexone, an orally semisynthetic opiate antagonist, is FDA- approved for treatment of heroin/ alcohol addiction, but there have been observations that low dose naltrexone (LDN) can mitigate fatigue and stress in fibromyalgia and multiple sclerosis patients. While the mechanism is largely not understood, LDN is thought to work as a partial agonist and lead to transient increases in met-enkephalin and β-endorphins, which in turn can theoretically improve energy and QoL. Objective: Because of the lack of toxicity and paucity of agents to mitigate fatigue and improve QoL, we sought to evaluate LDN effect of QoL and fatigue in newly diagnosed HGG. Methods: In a placebo-controlled, double-blind, randomized study, HGG patients received placebo or LDN (4.5 mg po qhs). Treatment began on the first day of chemoradiation and continued for 16 wks. The primary objective was to compare patient-reported outcome measures of QoL, including the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Safety of LDN was a secondary outcome with standard laboratory testing and adverse event reporting. Results: 110 subjects were randomized to LDN (54) or placebo (56). Subjects were: WHO grade IV (85[percnt]), male (56[percnt]), KPS 90-100 (51[percnt]), grossly resected (55[percnt]) and mean age of 56 years. Percent decrease from baseline at 16 weeks was not significantly different for FACT-Br [T-test p=0.4938; Mean=1.5 (LDN), 5.0 (placebo)]. Percent decrease from baseline at 16 weeks was not significantly different for FACIT-F [Wilcoxon p=0.3082; Median=6.9 (LDN), 11.8 (placebo)]. Adverse events were seen in similar frequencies in both groups. Conclusions: Though LDN is safe to administer, LDN has no impact on QoL or fatigue in HGG patients.

Disclosure: Dr. Peters has nothing to disclose. Dr. Affronti has nothing to disclose. Dr. Woodring has nothing to disclose. Dr. Lipp has nothing to disclose. Dr. Healy has nothing to disclose. Dr. McSherry has nothing to disclose. Dr. Herndon has nothing to disclose. Dr. Flahiff has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Freeman has nothing to disclose. Dr. Minchew has nothing to disclose. Dr. Zalutsky has nothing to disclose. Dr. Taylor has nothing to disclose. Dr. Boulton has nothing to disclose. Dr. Randazzo has nothing to disclose. Dr. DesJardins has nothing to disclose. Dr. Vlahovic has nothing to disclose. Dr. Bigner has nothing to disclose. Dr. Friedman has nothing to disclose.

Wednesday, April 22 2015, 7:30 am-12:00 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hastening the Diagnosis of Amyotrophic Lateral Sclerosis

Dr. Brian Callaghan and Dr. Kellen Quigg

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 101 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise